Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...
CDE Introduces New Guidelines for Generic Drug Quality and Efficacy Consistency Evaluation
The Center for Drug Evaluation (CDE) has released a new set of Guidelines for “the...
Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment
Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug...
Abbisko Therapeutics’ Irpagratinib Receives FDA Clearance for Phase I Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Sino Biopharmaceutical Submits IND Application for AT2R Antagonist TRD205 to FDA
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has announced the filing of...
Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses...
J&J and HHS Expand Public Health Initiative with Asha Therapeutics
Johnson & Johnson (J&J; NYSE: JNJ) and the US Department of Health and Human Services...
CDC Provisionally Recommends Pfizer’s Abrysvo for Maternal Immunization Against RSV
The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for...
Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US...
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...
Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing...
3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales
China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first...
Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor
Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation...
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised...
CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge
The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences...
Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license...
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises...
Sanofi’s Dupixent Secures NMPA Approval for Pruritigo Nodosa Treatment in China
France-based pharmaceutical company Sanofi (NASDAQ: SNY) has announced that it has received another indication approval...